Nuclear Medicine in Oncology

Alison Dorothy Murray, Margaret E Brooks

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The role of the nuclear medicine department in the diagnosis and management of malignant disease is constantly evolving. For example, the development of new radiopharmaceuticals, such as indium-111-labelled octreotide (pentetreotide), has enabled more specific imaging for the diagnosis of gastroentero-pancreatic (GEP) endocrine tumours to be carried out. New techniques such as sentinel lymph node localisation and biopsy now allow less invasive tumour staging. Advances in chemotherapy necessitate careful monitoring of the effects of chemotherapeutic drugs on normal organ function during follow-up, and tumour specific radiopharmaceuticals are being used for non-invasive, targeted tumour therapy. Nuclear medicine investigations should always be interpreted in the knowledge of results of other imaging investigations if they are to have greatest impact on patient care.

Original languageEnglish
Pages (from-to)110-119
Number of pages10
JournalJournal of the Royal College of Surgeons of Edinburgh
Volume45
Issue number2
Publication statusPublished - Apr 2000

Keywords

  • oncology
  • radiopharmaceuticals
  • diagnosis
  • staging
  • therapy
  • follow-up

Fingerprint Dive into the research topics of 'Nuclear Medicine in Oncology'. Together they form a unique fingerprint.

  • Cite this